

+



Substitute for form 1448A/PTO

(use as many sheets as necessary)

Sheet

1

of

3

Application Number	09/733,801
Filing Date	12/09/2000
First Named Inventor	JOHNSON David K
Group Art Unit	1621
Examiner Name	
Attorney Docket Number	60/17024

[illegible][illegible]

**Examiner
Signature**

Date _____

Considered

12/13/04

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/733,801
Filing Date	12/09/2000
First Named Inventor	JOHNSON David K.
Group Art Unit	1621
Examiner Name	
Attorney Docket Number	Johnson 60/17024

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DV	1	SUNDBERG MW, Meares CF, Goodwin DA, and Diamanti CI. "Selective binding of metal ions to macromolecules using bifunctional analogs of EDTA." J. Med. Chem. 17 (12), 1304-1307 (1974).	
	2	BRECHBIEL MW, Gansow OA, Atcher RW, Schlom J, et al. "Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies." Inorg. Chem. 25, 2772-2781 (1986).	
	3	BRECHBIEL MW and Gansow OA. "Backbone-substituted DTPA ligands for ⁹⁰ Y radioimmunotherapy." Bioconjugate Chem. 2, 187-194 (1991).	
	4	MEARES CF, et al. "Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions." Analyt. Biochem. 142, 68-78 (1984).	
	5	GOODWIN DA, et al. "Pre-targeted immunoscintigraphy of murine tumors with Indium-111-labeled bifunctional haptens." J. Nucl. Med. 29, 226-234 (1988).	
	6	BLAKE DA, et al. "Metal binding properties of a monoclonal antibody directed toward metal-chelate complexes." J. Biol. Chem. 271(44), 27677-27685 (1996).	
	7	KHOSRAVIANI M, et al. "Detection of heavy metals by immunoassay: optimization and validation of a rapid, portable assay for ionic cadmium." Environ. Sci. Technol. 32, 137-142 (1998).	
	8	CHAKRABARTI P, et al. "Enzyme immunoassay to determine heavy metals using antibodies to specific metal-EDTA complexes: optimization and validation of an immunoassay for indium." Analyt. Biochem. 217, 70-75 (1994).	
	9	BRINKLEY M. "A brief survey of methods for preparing protein conjugates with dyes, haptens, and cross-linking reagents." Bioconjugate Chem 3, 2-13 (1992).	
	10	LE DOUSSAL J-M, et al. "Targeting of Indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted by nude mice." Cancer Res. 50, 3445-3452 (June 1, 1990).	
	11	JOLLEY M. "Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma." J. Analyt. Toxicol 5, 235-240 (September/October 1981).	

Examiner
Signature

[Signature]


Date
Considered

12/13/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1448B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number 09/733,801
Filing Date 12/09/2000
First Named Inventor JOHNSON David K.
Group Art Unit 1621
Examiner Name
Attorney Docket Number Johnson 60/17024

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DU	1	DANDLIKER WB, <i>et al.</i> "Fluorescence polarization immunoassay. Theory and experimental method." Immunochem. 10, 219-227 (1973).	
	2	OGAN MC, <i>et al.</i> "A specific radioimmunoassay for the measurement of gadoteridol, a contrast agent for magnetic resonance imaging in biological fluids." J. Pharm. Sci. 82 (5), 475-479 (May 1993).	
		REARDAN DT, <i>et al.</i> "Antibodies against metal chelates." Nature 316, 265-268 (July 1985).	
	3	KHOSRAVIANI M, <i>et al.</i> "Binding properties of a monoclonal antibody directed toward lead-chelate complexes." Bioconjugate Chem. 11, 267-277 (2000).	
	4	DARWISH IA and Blake DA. "One-step competitive immunoassay for cadmium ions: development and validation for environmental water samples." Analyt. Chem. 73 (No. 8), 1889-1895 (April 15, 2001).	
		ADAMCZYK M, <i>et al.</i> "Synthesis of immunocomponents for the measurement of lead (Pb) by fluorescence polarization immunoassay." Tetrahedron 54, 3093-3112 (1998).	
	5	BRECHBIEL MW and Gansow OA. "Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepentaacetic acids for labelling of monoclonal antibodies with a emitter." J. Chem. Soc. Perkin Trans. 1, 1173-1178 (1992).	

Examiner Signature *D. Johnson* Date Considered 12/13/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.